
Chemed (($CHE)) has held its Q3 earnings call. Read on for the main highlights of the call. Chemed’s third-quarter call carried a strongly positive tone, led by sharp VITAS growth,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CHE | Chemed | 548.59 | 109.15 | 24.84% |
| Name | Price | % Change | |
|---|---|---|---|
| $548.59 | +24.84% |

Chemed (($CHE)) has held its Q3 earnings call. Read on for the main highlights of the call. Chemed’s third-quarter call carried a strongly positive tone, led by sharp VITAS growth,

Meetings to be held in Boston on November 3-4 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s

RBC Capital raised the firm’s price target on Chemed (CHE) to $585 from $548 and keeps a Sector Perform rating on the shares. The company posted another strong result in

UBS raised the firm’s price target on Chemed (CHE) to $675 from $650 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Oppenheimer raised the firm’s price target on Chemed (CHE) to $625 from $590 and keeps an Outperform rating on the shares following quarterly results, with Vitas strength outweighing Roto-Rooter margin

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

BofA raised the firm’s price target on Chemed (CHE) to $555 from $550 and keeps a Neutral rating on the shares. Q3 EBITDA beat by 2% and EPS beat by

Jefferies upgraded Chemed (CHE) to Buy from Hold with a price target of $620, up from $520. The firm expects the shares to “gradually re-rate” toward 15-times EBITDA as the

Reports Q3 revenue $690.94M, consensus $685.04M. The company said, “As of September 30, 2026, Chemed (CHE) had total cash and cash equivalents of $48.4 million and $236.0 million in long-term

The company said, “Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $7.18B | $7.35 | $711.93M | -2.78 | 26.18 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.